Shorts are praying for a dip in the market to cover the naked shorts they have to add in a strong market to keep ARNA price under control. If they fail they can always count on an insider sale, or some other stupid ARNA exec move to bail them out. Where's the S1P1 data JL? Where's the pipeline value?
Shorts have a grip on ARNA, but maybe not for much longer. Word will spread about the S1P1 drug and those wanting what RCPT has will invest. IMO, not advice.
For those smart and fortunate enough to invest in RCPT, take a look at ARNA, they have a similar drug, earlier stage and a much lower market cap and a decent pipeline. Management is the weakness. ARNA has a very large short position, so there is the potential for a nice rise if they start to get some buy volume.
It's clear that Jack is a weak business pro. He's also not a scientist, so I'm not sure how he is qualified to be a CEO other than bribing the other BOD members to back him.
someone is going to want to invest in 334 assuming ARNA execs are telling the truth about its potential and early clinical results. New 1-month high $4.5 is next test.
OK short it then, you go first! You surely know more than JNJ execs that evaluated the co and invested hundreds of $ millions!
Teva would be a fine owner, they have the people to make Belviq sell now and to develop the pipeline. ARNA execs (with the exception of Craig A) are clueless and not shareholder focused.
It's a great job if you can get it, 6 figures, Switzerland seems like no accountability, but who knows. BD is the loneliest job at ARNA. Chief dilution officer is much more active.
I asked them if they had looked into the June 12 rapid decline incident and what competitive threats were on the radar screen. I'm sure they will say we take all potential incidents seriously and we actively monitor the competitive landscape...Let's see if we get any detailed info.
It's the shareholders that own the company and they should decide!
Looks like Jack is buying and owning the BOD with 40,000+ free shares. What a joke, these people have done nothing for the shareholders. They should all be fired! Hopefully they noticed the significant uptick in votes against.
Yahoo erased my first post, so I will try again. In the many years I've been following/investing in ARNA Hoffman did one good thing, a well-timed offering. Under his leadership ARNA did some bad borrowings from the likes of DF and another shady biotech loan shark co, forgot the name. ARNA needs to cut cost/fat/waste. Other than cutting Jack, this was the 2nd best choice. Hopefully more fat cutting to follow. Hope that was tame enough for the free speech sensors.
looks like a lot of that growth is already priced in. A good buy at $40?